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Background: The phase III EXTREME study demonstrated that combining cetuximab with platinum/5-ﬂuorouracil
(5-FU) signiﬁcantly improved overall survival in the ﬁrst-line treatment of patients with recurrent and/or metastatic
squamous cell carcinoma of the head and neck (R/M SCCHN) compared with platinum/5-FU alone. The aim of this
investigation was to evaluate elevated tumor EGFR gene copy number as a predictive biomarker in EXTREME study
patients.
Patients and methods: Dual-color FISH was used to determine absolute and relative EGFR copy number. Models
of differing stringencies were used to score and investigate whether increased copy number was predictive for the
activity of cetuximab plus platinum/5-FU.
Results: Tumors from 312 of 442 patients (71%) were evaluable by FISH and met the criteria for statistical analysis. A
moderate increase in EGFR copy number was common, with high-level ampliﬁcation of the gene occurring in a small
fraction of tumors (11%). Considering each of the models tested, no association of EGFR copy number with overall
survival, progression-free survival or best overall response was found for patients treated with cetuximab plus
platinum/5-FU.
Conclusion: Tumor EGFR copy number is not a predictive biomarker for the efﬁcacy of cetuximab plus platinum/
5-FU as ﬁrst-line therapy for patients with R/M SCCHN.
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introduction
The randomized phase III EXTREME study demonstrated that
the addition of cetuximab to platinum/5-ﬂuorouracil (5-FU)
chemotherapy statistically signiﬁcantly improved overall
survival when given as ﬁrst-line treatment to patients with
recurrent and/or metastatic squamous cell carcinoma of the
head and neck (R/M SCCHN) compared with platinum/5-FU
alone (median 10.1 versus 7.4 months, hazard ratio 0.80,
P = 0.04) [1]. The addition of cetuximab to platinum/5-FU also
led to signiﬁcant improvements in progression-free survival
(PFS) and best overall response rate, which was approximately
doubled. Safety analysis demonstrated that the combination
was feasible, with a manageable side-effect proﬁle. The 2.7-
month median survival time beneﬁt associated with the
addition of this epidermal growth factor receptor (EGFR)-
targeted monoclonal antibody to standard platinum-based
chemotherapy represents the most signiﬁcant advance in the
treatment of the disease in this setting for 30 years. These data
complement an earlier study in locally advanced SCCHN which
showed that the addition of cetuximab to radiotherapy
conferred a long-term survival beneﬁt compared with
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survival beneﬁt at 5 years) was similar to that achievable in this
setting with chemoradiotherapy [2–5].
Recent studies have shown that the clinical impact of EGFR-
targeted therapies can be increased if treatment administration
can be tailored to particular subpopulations of patients whose
tumors have speciﬁc molecular alterations [6, 7]. Elevated gene
copy number, which may arise within a tumor cell as the result
of an increase in the numbers of chromosomes encoding the
gene (polysomy) or may occur as a consequence of local
ampliﬁcation of a chromosomal region (gene ampliﬁcation), is
a somatic event with potential predictive utility. Increased copy
number may indicate that a tumor is highly dependent on the
activity of an ampliﬁed gene for continued proliferation and/or
survival, a situation described as oncogene addiction [8]. In this
case, the tumor may be particularly sensitive to anticancer
agents that target the product of that gene and elevated copy
number may consequently be a predictive biomarker, as
exempliﬁed by ERBB2 gene ampliﬁcation in breast cancer and
sensitivity to trastuzumab [9]. Copy number can be evaluated
in tumors and the two different causal genetic mechanisms can
be distinguished through the use of dual-color FISH analysis
incorporating a gene-speciﬁc probe combined with
a centromere-speciﬁc probe for the chromosome encoding
that gene.
The data on the impact of EGFR gene copy number status on
cetuximab efﬁcacy in metastatic colorectal cancer (mCRC) and
non-small-cell lung cancer (NSCLC) is contradictory. While
some studies reported an association of high EGFR gene copy
number and improved outcome in mCRC and NSCLC patients
receiving cetuximab [10–14], other studies failed to identify
similar associations [15–17]. No data on EGFR gene copy
number and cetuximab efﬁcacy have so far been reported for
SCCHN.
Expressed in 90%–100% of tumors, up-regulation of
EGFR appears to be an early marker of SCCHN carcinogenesis
[18–20], and high-level tumor expression has been correlated
with poor clinical outcome [21]. Elevation of EGFR copy
number is a characteristic somatic event that occurs in the
development of this disease and may additionally be an
indicator of poor prognosis [22, 23]. The aim of the current
study was to investigate in the large relatively homogeneous
population recruited for the randomized phase III
EXTREME study whether elevated tumor EGFR copy
number was predictive for the activity of cetuximab plus
platinum/5-FU, administered as ﬁrst-line therapy to patients
with R/M SCCHN.
patients and methods
EXTREME study design
As previously reported [1], inclusion criteria included age ‡18 years,
untreated R/M SCCHN, ineligibility for local therapy, Karnofsky
Performance Score of ‡70% and adequate organ function. Patients were
excluded if they had received prior surgery or radiotherapy within 4 weeks
of study entry or prior systemic chemotherapy (apart from for locally
advanced disease).
Patients were randomly assigned to receive every 3 weeks for up to six
cycles either cisplatin, 100 mg/m
2 day 1, or carboplatin area under the curve
of 5 day 1 (physician’s choice); plus 5-FU infused at 1000 mg/m
2/day for
4 days either with or without cetuximab, administered at an initial dose of
400 mg/m
2 and then 250 mg/m
2 weekly, both during chemotherapy and
subsequently as maintenance therapy until the occurrence of disease
progression or unacceptable toxicity. The primary end point was overall
survival. Secondary end points included PFS, best overall response, disease
control, time-to-treatment failure, duration of response and safety.
collection and storage of patient material
All patients provided written informed consent for EGFR testing on tumor
samples. All available formalin-ﬁxed parafﬁn-embedded (FFPE) tumor
tissue specimens from patients in the clinical study (blocks and slides) were
analyzed at a central laboratory (Wuppertal Institute of Pathology,
Wuppertal, Germany) according to a standard protocol.
FISH analysis
FISH analysis was carried out on deparafﬁnized 3- to 5-lm FFPE sections
using the prepared solutions and protocol provided in the Histology FISH
Accessory Kit (Dako, Denmark; see supplemental Methods, available at
Annals of Oncology online). EGFR copy number was assessed using an
EGFR/CEN-7 FISH probe mix (Dako). Fluorescence was visualized using
a DM50000 B (Leica, Germany) ﬂuorescence microscope with a DAPI ﬁlter
and a Texas Red double ﬁlter. EGFR (normal location 7p11.2) signals
appeared red and CEN-7 signals (probe homologous to the centromeric
region of chromosome 7) appeared green.
statistical methods
The FISH investigation was a retrospectively planned exploratory analysis.
For a patient to be included, a target of 100 evaluable (where a signal was
present for both EGFR and CEN-7) cells and a minimum of 50 cells were to
be assessed. Patients from the intention-to-treat (ITT) population with
FISH assessments for at least 50 cells formed the FISH ITT population. For
each analyzed cell, observed EGFR/CEN-7 signals were used to determine
absolute and relative EGFR copy numbers. Average (mean) signal counts or
ratios per patient were calculated.
Given the possibility that the most appropriate scoring system to assess
the association of copy number changes and clinical outcome may vary
according to the disease or the particular stage of disease, a series of
different systems were used to deﬁne FISH-positive (elevated EGFR copy
number) and FISH-negative (nonelevated EGFR copy number) status in R/
M SCCHN, including ﬁve predeﬁned EGFR enrichment models and the
Colorado scoring system, previously developed for the analysis of EGFR
copy number in NSCLC (Table 1) [12, 24].
EGFR enrichment models
EGFR enrichment models were evaluated in both treatment groups of the
study. Five different models were developed using different thresholds to
deﬁne each analyzed cell as FISH positive or negative. To derive a factor
representative of the degree of heterogeneity across the tumor cells sampled
for each patient, the percentage of FISH-positive tumor cells (of those
analyzed) was then calculated for each patient and model (FISH score;
ranging from 0% to 100%). For each model, for patients in each study arm,
these values were used to construct scatter plots of survival time and PFS
time versus the FISH score. These plots were subsequently assessed both
visually and statistically (see supplemental Methods, available at Annals of
Oncology online) in an attempt to identify a particular threshold value that
allowed for a signiﬁcant enrichment of patients with a survival beneﬁt
according to EGFR copy number status. For each model, for each arm, box
plots of best overall response according to FISH score were also constructed
and assessed visually to determine whether a clear correlation was apparent
between tumor response and EGFR copy number.
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EGFR copy number was also deﬁned for patients in each study arm
according to the previously established Colorado scoring system (Table 1).
This system differed from the enrichment models in that it allowed the
classiﬁcation of tumors (rather than individual tumor cells) as either FISH
positive or negative. The association of FISH status according to the
Colorado system with clinical outcome was investigated using log-rank
(PFS and overall survival) and Cochran–Mantel–Haenszel (response) tests.
results
patient population and material
Tumor tissue samples were available from 381 of the 442 (86%)
patients in the ITT population of the EXTREME study. Samples
from 312 patients (71%) were evaluable by FISH and met the
criteria for statistical analysis (FISH ITT population; Table 2).
Treatment arms were essentially balanced with respect to the
number of evaluable samples, with 158 deriving from patients
receiving cetuximab plus chemotherapy (71%) and 154 from
those receiving chemotherapy alone (70%). The effects of
treatment in relation to overall survival, PFS and best overall
response were comparable for the ITT and FISH ITT
populations (see supplemental Table 1, available at Annals of
Oncology online).
FISH analysis
Dual-color FISH analysis was carried out to evaluate for each
tumor the number of signals in each cell related to EGFR and to
the centromeric region of chromosome 7. Representative
images from these assays are shown in Figure 1. The average
numbers of EGFR and CEN-7 signals and the average ratio of
EGFR/CEN-7 signals were calculated for the tumors of patients
in each arm and in the overall FISH ITT population (Table 3).
The decimal fraction of cells with EGFR signal clusters was also
determined.
The distributions of the average signal counts for EGFR and
CEN-7 and the EGFR/CEN-7 ratio were comparable between
the two treatment groups. Tumor EGFR gene copy number was
elevated in a substantial fraction of patients, with 40% of the
FISH ITT population having average EGFR signal counts per
cell of >3 and 11% of >5 (Table 3). The observed elevation of
tumor EGFR gene copy number was due to both polysomy
events (27% of patients had average CEN-7 signal counts of >3)
and local ampliﬁcation (12% of patients had an average cellular
EGFR/CEN-7 ratio of >2). In 13% of patients, a fraction of
tumor cells was scored as having strong localized EGFR
ampliﬁcation, such that individual signals could not be
distinguished (clusters): 11% of patients had such clusters
in ‡25% of tumor cells (Table 3).
As there was no known EGFR copy number threshold value
that might be of predictive utility in this setting, a series of
models with different stringencies were designed to provide
deﬁnitions, which could be used to assign FISH status
(Table 1). These models were then used to assess whether
elevated EGFR copy number, as deﬁned in each model, was
predictive for cetuximab efﬁcacy.
Table 1. FISH scoring systems
Scoring systems and models Deﬁnitions
EGFR enrichment model for evaluation of FISH status
Model A
FISH positive EGFR/CEN-7 ratio ‡2 or presence
of EGFR signal cluster
Model B
FISH positive EGFR signal count ‡3 or presence
of EGFR signal cluster
Model C
FISH positive EGFR signal count ‡6 or presence
of EGFR signal cluster
Model D
FISH positive EGFR/CEN-7 ratio ‡2 or presence
of EGFR signal cluster or EGFR
signal count ‡3
Model E
FISH positive EGFR/CEN-7 ratio ‡2 or presence
of EGFR signal cluster or EGFR
signal count ‡6
Colorado scoring system
FISH positive ‡40% of cells display ‡4 EGFR counts
or the presence of gene ampliﬁcation,
as deﬁned by either
Mean EGFR/CEN-7 ratio ‡2
>10% of cells displaying >15 EGFR
counts
>10% of the cells displaying the
presence of loose or tight EGFR
signal clusters or atypically large
EGFR signals (EGFR cluster
scored)
CEN-7, probe for centromeric region of human chromosome 7.
Table 2. ITT patients assessed for EGFR tumor gene copy number by
FISH
Patients, n (%) Cetuximab +
chemotherapy
Chemotherapy
alone
Randomly assigned to
treatment (ITT population)
222 (100) 220 (100)
FISH assessments not
performed
28 (13) 33 (15)
FISH assessments performed 194 (87) 187 (85)
FISH results not available
a 35 (16) 33 (15)
Assessment not possible
for technical reasons
29 (13) 23 (10)
Excluded from statistical
analysis (sample taken
after ﬁrst dose of
cetuximab)
11 (5) 12 (5)
FISH results available 159 (72) 154 (70)
FISH results available for ‡50 cells
(FISH ITT population)
158 (71) 154 (70)
FISH results for <50 cells 1 (0.5) 0
aBoth reasons may apply.
ITT, intention to treat.
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For each evaluable tumor, a FISH score was determined
according to one of the ﬁve different enrichment models (Table
1). The distribution of FISH scores was comparable between
subgroups of tumor samples from the invasive front and tumor
center (data not shown). As expected, the median FISH score in
models A, C and E which used more stringent criteria for
deﬁning a FISH-positive cell was markedly lower than in
models B and D, which used less stringent criteria
(supplemental Figure 1, available at Annals of Oncology online).
In an initial exploration of the predictive potential of EGFR
FISH status, scatter plots were constructed for each model for
survival time versus the respective FISH score for patients in
both study arms (Figure 2A). These plots did not demonstrate
Figure 1. Representative FISH analyses showing tumors comprising cells with (A) normal gene copy number (two signals for each probe per cell); (B) high-
level EGFR gene ampliﬁcation, as demonstrated by the presence of large EGFR signal clusters; (C) low/moderate-level gene ampliﬁcation, as demonstrated
by the presence of small EGFR signal clusters; (D) polysomy, as demonstrated by >2 EGFR/CEN-7 signals per cell; (E) heterogeneity for EGFR copy number,
with only a subpopulation showing high-level gene ampliﬁcation and (F) heterogeneity for EGFR copy number, with certain cells showing polysomy and
others, normal copy numbers.
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time for any model, in either study arm. The process was
repeated for each model for the analysis of PFS time versus the
respective FISH score for patients in both study arms (Figure
2B), with similar results. Evaluation of the misclassiﬁcation
error rates further supported the lack of predictive utility of
EGFR FISH status in relation to overall survival and PFS (see
supplemental Results, available at Annals of Oncology online).
Box plots of FISH score versus best overall response for each
model were also constructed. As for the other efﬁcacy end
points, these plots did not show a visible correlation between
parameters (Figure 2C).
Colorado model
The Colorado model (Table 1) was used to deﬁne tumor EGFR
FISH status for patients in both study arms. Treatment
outcome was then assessed according to FISH status. Using this
scoring system, 32% of patients were deemed to have EGFR
FISH-positive tumors. No signiﬁcant association was apparent
for this model between elevated EGFR copy number and overall
survival, PFS or best overall response (Table 4).
discussion
The collection of tissue samples during the course of large
randomized studies in different settings provides a powerful
platform to assess the predictive potential of candidate
biomarkers, with the analysis of the control arm allowing
discrimination between effects, which are prognostic for
standard treatment or predictive for the experimental therapy
[25]. Evaluation in such individual studies is important as
particular mutational or epimutational events which may occur
across various tumor types can have different phenotypic
consequences in different cell types or against a background of
other disease-typical genetic lesions. Consequently, the same
mutational event may be predictive for a treatment agent in one
tumor type and not another. This has been exempliﬁed in the
case of cetuximab by the contrasting data from randomized
studies in advanced colorectal cancer and advanced NSCLC,
where KRAS codon 12/13 mutations are predictive for
treatment beneﬁt for cetuximab plus standard chemotherapy
compared with chemotherapy alone in the former setting [26,
27] but not the latter [16, 17]. The consequence of such
ﬁndings is that the potential utility of predictive biomarkers
cannot be assumed to be generalizable for a given agent and
must be assessed speciﬁcally in each tumor type and in
each treatment setting. In relation to SCCHN, KRAS is mutated
(at least in the above-mentioned codons) in only a small
fraction of cases [28–30], and therefore, KRAS status is not
likely to be a useful predictive marker for cetuximab beneﬁt in
this disease.
The current study, the largest of its type in this setting, which
included an extensive series of tumor samples from 312
patients, represents a truly comprehensive analysis investigating
the inﬂuence of a disease-relevant candidate biomarker, EGFR
copy number status, on clinical outcome in patients with R/M
SCCHN treated with cetuximab plus platinum-based
chemotherapy as part of a large randomized phase III study. As
Table 3. Average signal counts following FISH analysis (FISH ITT
population)
FISH evaluations Cetuximab +
chemotherapy,
n = 158
Chemotherapy
alone, n = 154
FISH ITT
population,
n = 312
CEN-7
Average numbers of signals/cell, n
Median of all
patients (range)
2.3 (1.1–6.2) 2.4 (1.2–5.8) 2.3 (1.1–6.2)
Mean of all
patients (SD)
2.5 (0.88) 2.5 (0.82) 2.5 (0.85)
Patients in categories deﬁned by
average number of signals/cell, n (%)
1–2 61 (39) 50 (32) 111 (36)
>2–3 57 (36) 61 (40) 118 (38)
>3–4 33 (21) 33 (21) 66 (21)
>4 7 (4) 10 (6) 17 (5)
EGFR
Average numbers of signals/cell, n
Median of all
patients (range)
2.6 (1.1–26.8) 2.8 (1.0–43.2) 2.7 (1.0–43.2)
Mean of all
patients (SD)
3.4 (3.26) 4.1 (4.77) 3.7 (4.08)
Patients in categories deﬁned by
average number of signals/cell, n (%)
1–2 48 (30) 40 (26) 88 (28)
>2–3 50 (32) 49 (32) 99 (32)
>3–4 36 (23) 35 (23) 71 (23)
>4–5 9 (6) 10 (6) 19 (6)
>5 15 (9) 20 (13) 35 (11)
EGFR/CEN-7 ratio
Average signal ratio/cell
Median of all
patients (range)
1.0 (0.6–10.7) 1.1 (0.5–20.8) 1.1 (0.5–20.8)
Mean of all
patients (SD)
1.5 (1.57) 1.9 (2.57) 1.7 (2.13)
Patients in categories deﬁned by
average signal ratio/cell, n (%)
0–1 24 (15) 17 (11) 41 (13)
>1–2 119 (75) 116 (75) 235 (75)
>2 15 (9) 21 (14) 36 (12)
EGFR signal clusters
Decimal fraction of cells per
patient with EGFR signal cluster present
Median of all
patients (range)
a
0 (0–1.0) 0 (0–1.0) 0 (0–1.0)
Mean of all
patients (SD)
0.1 (0.24) 0.1 (0.30) 0.1 (0.27)
Patients in categories deﬁned by
decimal fraction of cells with clusters
b, n (%)
0 139 (88) 132 (86) 271 (87)
>0t o<0.25 5 (3) 3 (2) 8 (3)
0.25–0.75 5 (3) 3 (2) 8 (3)
>0.75 to <1 8 (5) 9 (6) 17 (5)
1 1 (0.6) 7 (5) 8 (3)
a0 = no cluster in any cell; 1 = clusters in every cell.
bFor example, 0.25 equates to 25% of cells having clusters.
CEN-7, probe for centromeric region of human chromosome 7; ITT,
intention to treat; SD, standard deviation.
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1082 | Licitra et al. Volume 22|No. 5|May 2011Figure 2. Scatter and box plots did not demonstrate an association between FISH score and (A) overall survival time, (B) progression-free survival (PFS)
time or (C) best overall response, for patients in either study arm, when EGFR copy number was analyzed according to enrichment models A–E, as
indicated. The upper and lower boundaries of each box plot represent the 25th and 75th percentile and the horizontal lines within the box represent the
median values. The bars extend to the last observation not deﬁned as an extreme value (represented by + symbols) or to the minimum/maximum values if
an extreme value was not identiﬁed. CR, complete response; CT, chemotherapy; NE, not evaluable; PD, progressive disease; PR, partial response; SD, stable
disease.
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for abnormal copy number on which this and future
similar studies could be based had to be determined. By
using different enrichment models and calculating a FISH score
for each tumor, a broad spectrum of thresholds (from
moderate to high) was tested. In addition to these models, the
Colorado scoring system, which has been used to demonstrate
the predictive utility of EGFR gene copy number in NSCLC
Figure 2. (Continued)
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setting.
Considering each of these models covering a range of
stringencies, no association of EGFR copy number status with
overall survival, PFS and best overall response was found. Given
the extensive nature of this analysis, it seems reasonable to
conclude that EGFR copy number status as determined by FISH
is not a predictive biomarker for the efﬁcacy of cetuximab
combined with platinum/5-FU in the ﬁrst-line treatment of
R/M SCCHN. Although there was a trend for a higher response
rate in patients receiving chemotherapy alone with EGFR FISH-
negative compared with FISH-positive tumors, according to the
Colorado scoring system, no robust association between EGFR
copy number status and any efﬁcacy measure was detected in
the overall study population (data not shown). Thus, EGFR
copy number status does not appear to be a prognostic marker
in this setting.
High EGFR copy number was previously found to be a
marker of poor prognosis in a FISH analysis of a heterogeneous
population of 82 patients with SCCHN, 75 of whom were
assessable for FISH [22]. Seventy-two primary tumor blocks
were initially available from patients who had received no
prior anticancer treatment and 14 from patients with recurrent
tumors (four paired samples). All patients in the survival
analysis were treated with curative intent. The difference
between this and the current study in relation to the assessment
of the prognostic potential of EGFR copy number may be due
to the dissimilarity of the patient populations analyzed (R/M
SCCHN in the current study versus potentially curable stages
I–IV patients in the previous study). Analyzed tissues in the
current study were essentially therefore derived from patients
with more advanced disease who were to receive palliative
treatment. In this context, we cannot derive a deﬁnitive Figure 2. (Continued)
Table 4. Colorado FISH status according to tumor site and efﬁcacy
according to FISH status (FISH ITT population)
Parameter Cetuximab + chemotherapy Chemotherapy alone
FISH+,
n = 50
FISH2,
n = 108
FISH+,
n = 51
FISH2,
n = 103
Overall survival time
Median, months 10.5 10.6 7.2 7.8
Hazard ratio
a
(95% CI)
1.02
(0.69–1.51)
1.04
(0.71–1.51)
P value 0.93 0.86
PFS time
Median, months 6.2 5.7 3.1 4.1
Hazard ratio
a
(95% CI)
0.86
(0.58–1.27)
1.05
(0.71–1.54)
P value 0.46 0.81
Best overall response
rate, %
36.0 34.3 11.8 22.3
Odds ratio
b
(95% CI)
1.08
(0.54–2.18)
0.46
(0.18–1.22)
P value 0.83 0.12
aHazard ratios <1 correspond to beneﬁt for FISH+ patients.
bOdds ratios >1 correspond to beneﬁt for FISH+ patients.
CI, conﬁdence interval; PFS, progression-free survival.
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curative intent with cetuximab since it could well be that EGFR
copy number has prognostic and/or predictive utility in this
setting.
In relation to the mean signal counts, 40% of tumors had
EGFR copy numbers of >3 and 11% of tumors had copy
numbers of >5. The tumor EGFR/CEN-7 ratio was >2 for 12%
of patients and 11% of patients had EGFR signal clusters
in ‡25% of their tumor cells. Applying the Colorado system,
32% of tumors were scored as EGFR FISH positive. Taken
together, these data indicate that a moderate increase in EGFR
copy number is a common event in SCCHN, with high-level
ampliﬁcation of the gene occurring in a small fraction of
tumors (11%).
The EGFR copy number data in the current study are in the
range of values reported from earlier FISH analyses [22, 23, 31,
32]. Two smaller studies using the Colorado scoring system
found incidences of FISH-positive tumors of 57% (43 of 75
patients) [22] and 13% (4 of 31 patients) [31], respectively.
Analyzing a large series of SCCHN samples using a tissue
microarray, Freier et al. [32] reported that 13% (63 of 496) of
tumors had 10% of cells showing ‡8 signals or tight signal
clusters from the gene-speciﬁc probe, which is comparable to
the incidence of high-level EGFR ampliﬁcation reported in this
study. However, it should be noted that even among patients in
the current study whose tumors had high-level increases in
EGFR gene copy number based on the more stringent
enhancement models, no clear distinction in relation to survival
beneﬁt was observed (Figure 2A).
In summary, the retrospective analysis of tissue collected
during the randomized phase III EXTREME study has
indicated that tumor EGFR copy number status is not
a predictive biomarker for the efﬁcacy of cetuximab plus
platinum/5-FU administered as ﬁrst-line therapy to patients
with R/M SCCHN. Therefore, analyzing EGFR copy number by
FISH in this setting before the administration of cetuximab
does not appear to provide any clinically relevant information
for the physician. This study has therefore shown that the
beneﬁt conferred by the addition of cetuximab to standard
chemotherapy for this disease is independent of tumor EGFR
copy number.
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